M. Chan

Rapid production of clinical‐grade SARS‐CoV‐2 specific T cells

J. Low, W. Chng, J. Loh, 2020, Advances in cell and gene therapy.

A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission.

C. Chuah, H. Ng, W. Hwang, 2012, Cytotherapy.

Large-scale Isolation of Highly Pure “Untouched” Regulatory T Cells in a GMP Environment for Adoptive Cell Therapy

O. Rotzschke, K. Puan, Nurhashikin Yusof, 2015, Journal of immunotherapy.

Clinical scale expansion of cytokine-induced killer cells is feasible from healthy donors and patients with acute and chronic myeloid leukemia at various stages of therapy.

G. Suck, S. Chu, M. Niam, 2011, Experimental hematology.

The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies

W. Hwang, G. Suck, S. Chu, 2012, Bone Marrow Transplantation.

Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit

John E. Connolly, B. Goh, B. Dharmadhikari, 2021, Cancer Immunology, Immunotherapy.